Gary W. Pace Purchases 15,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock

Key Points

• Gary W. Pace, a director at Cardiff Oncology, Inc., purchased 15,000 shares at an average price of $2.45, increasing his total ownership to 1,345,676 shares.
• Cardiff Oncology reported an EPS of ($0.21) for the last quarter, missing analyst expectations by two cents, while revenues slightly exceeded forecasts at $0.12 million.
• Analysts have a Moderate Buy rating on Cardiff Oncology, with prices targets as high as $19.00 from recent reports, indicating optimism about the company's potential growth.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) Director Gary W. Pace bought 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 30th. The shares were acquired at an average price of $2.45 per share, with a total value of $36,750.00. Following the acquisition, the director owned 1,345,676 shares of the company's stock, valued at $3,296,906.20. This represents a 1.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Cardiff Oncology Price Performance

Shares of NASDAQ CRDF traded down $0.12 during midday trading on Thursday, reaching $2.37. 4,714,578 shares of the stock traded hands, compared to its average volume of 1,404,724. The stock has a market capitalization of $157.68 million, a PE ratio of -2.72 and a beta of 1.52. The company's 50 day moving average is $3.61 and its 200 day moving average is $3.51. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $5.64.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 75.32%. The business had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.11 million. As a group, equities analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

CRDF has been the subject of a number of recent analyst reports. HC Wainwright upped their target price on Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a report on Friday, May 9th. Jefferies Financial Group began coverage on Cardiff Oncology in a research note on Tuesday, June 24th. They issued a "hold" rating and a $3.50 target price on the stock. William Blair reaffirmed an "outperform" rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th. Finally, LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a report on Tuesday, July 8th. They issued a "buy" rating and a $19.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cardiff Oncology has an average rating of "Moderate Buy" and an average price target of $11.70.

Hedge Funds Weigh In On Cardiff Oncology

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new stake in Cardiff Oncology during the fourth quarter valued at about $25,000. Baader Bank Aktiengesellschaft purchased a new position in Cardiff Oncology in the second quarter valued at about $32,000. Ledgewood Wealth Advisors LLC purchased a new position in Cardiff Oncology in the first quarter valued at about $35,000. Belpointe Asset Management LLC purchased a new position in Cardiff Oncology in the first quarter valued at about $37,000. Finally, Castleview Partners LLC purchased a new position in Cardiff Oncology in the first quarter valued at about $45,000. Hedge funds and other institutional investors own 16.29% of the company's stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.